Zydus gets USFDA approval for estradiol and levonorgestrel transdermal system
The product has been designated as a Competitive Generic Therapy and is eligible for a 180-day exclusivity period, subject to applicable provisions
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
